Rockville, MD, USA, Aug. 16, 2017 -- The Regulatory Affairs Professionals Society (RAPS) has published the updated, 10th edition of Fundamentals of US Regulatory Affairs, the most extensive reference available on regulatory affairs for pharmaceuticals, medical devices, biologics and other healthcare products intended for the US market. The book is an essential reference for anyone responsible for products that must comply with regulations from the US Food and Drug Administration (FDA) and other relevant US agencies.
|
||||||||
The first edition of US Fundamentals was introduced two decades ago and has undergone regular revisions over the years, reflecting changing regulations and new technologies. Fundamentals of US Regulatory Affairs, 10th Edition has been completely updated with information that is current as of May 2017. Notable changes from the previous edition include more detail in areas such as preclinical trials and Good Laboratory Practices, and clinical trials and Good Clinical Practices. New chapters have been added on traceability and supply chain, and biosimilars. In all, the book is comprised of 44 chapters by 53 regulatory experts.
In addition, for the first time, RAPS has also published two sector-specific US fundamentals books, Fundamentals of US Medical Device Regulations and Fundamentals of US Pharmaceutical & Biologics Regulations. Each one presents the same content published in the 10th edition, but only that which is related to either medical devices or pharmaceuticals and biologics, respectively. This allows those who work exclusively in one sector or the other to get all the information that is pertinent to them without additional content that may not be.
The list price for the full 10th edition is $395, while RAPS members get $100 off that price. Each of the sector-specific books is available for $225 list, and $175 for members. All are available in both print and e-book versions.
Since its introduction, US Fundamentals has sold more than 30,000 copies. It is relied upon by regulatory and legal professionals, professors, students, career-changers and FDA staffers as a valued reference, academic textbook and Regulatory Affairs Certification (RAC) study tool.
For more information or to order any of the fundamentals books, visit RAPS.org/fundamentals.
About RAPS
The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC), the only post-academic professional credential to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with chapters and affiliates worldwide. www.RAPS.org
###
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/f42a58a7-9328-488d-ba2f-3b0eb765e033
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/14d84e82-492a-4d4d-8719-c14b97005013
Zachary Brousseau Regulatory Affairs Professionals Society (RAPS) 301 770 2920, ext. 245 [email protected]


SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Tesla Launches New Model Y Variant in the US Starting at $41,990
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 



